This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing.
Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran. Great team work!!!
Check out the beautiful visual abstract made by NephJC intern Michelle Fravel.
El estudio NUDGE-CKD evaluó si enviar cartas electrónicas con recomendaciones a médicos y pacientes podía aumentar el uso de tratamientos clave en enfermedad renal crónica (iSRAA o iSGLT2).
Revisa el resumen visual por Divya Bajpal
¿El resultado? Hoy en vivo por #NephJC!
Check out the beautiful visual abstract made by NephJC faculty Dr Divyia Bajpai
Metformin in stage 4 CKD? Catch-up here
Should we continue metformin in eGFR under 30 ml/min? The visual abstract by Cristina Popa summarizes the conclusions from the Scottish cohort using target trial methodology.
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
Does initiation of ACEi and ARB help in advanced CKD? Check out the VA by Dr Nikhil John
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (Ku, JASN 2023)
CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction (Mahdavi, JAMA Network Open 2023)
